In vivo CAR-T cell therapy and its technologies: A perspective
用户SfWBTfZVQt4c
13天前
34
10
已完结
1. 系统已在2025-11-25 16:16:00对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
S Zhou, C Xu, J Wang
Science China Technological Sciences, 2025
Springer
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment landscape for relapsed and refractory haematological malignancies [1]. Despite its remarkable clinical success, the ex vivo manufacturing of autologous CAR-T cells remains costly, time-consuming, and logistically burdensome. To address these limitations, in vivo engineering of CAR-T cells—whereby functional CAR-T cells are generated directly within the patient
